MetaCap

Alector (ALEC) vs TRex Bio (TRXB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alector is the larger company by market cap ($347.6 million vs $297.0 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALEC+12.26%TRXB-26.32%
+29%-3%-36%
Oct 9, 20261 yearNov 20, 2026
ALEC+12.26%TRXB-26.32%
+25%-2%-29%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALEC versus TRXB key metrics
MetricALECTRXB
Share price$2.34$10.32
Market cap$347.63M$296.95M
1-day change+1.52%+6.12%
YTD return+49.68%—
1-year return+88.31%—
5-year return-88.28%—
P/E ratio (TTM)6.31—
EPS (TTM)$0.37$-2.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$21.05M—
Revenue growth (YoY)-79.07%—
Net income (latest FY)$-142.93M—
Operating margin-741.30%—
Net margin-679.16%—
52-week high$2.84$16.56
52-week low$1.09$9.06
Distance from 52-week high-17.78%-37.71%
Analyst consensusbuystrong_buy
Avg. price target upside+89.29%+183.57%
Average volume3.34M156.80K
Shares outstanding148.88M28.79M
Employees10360
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Alector

ALEC stock →

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees

About TRex Bio

TRXB stock →

TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

ALEC vs TRXB FAQ

Which is bigger, Alector or TRex Bio?

Alector (ALEC) is larger, with a market capitalization of $347.63M compared with $296.95M for TRex Bio (TRXB).

Are Alector and TRex Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons